Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Foray Into Academia

Executive Summary

Novartis' decision to relocate its discovery operation to Cambridge, MA has garnered considerable attention for what it says about the decline of Europe's competitiveness in the pharmaceutical industry and the increasing attraction of the Boston area for drug and biotech firms. But perhaps even more significant is what the transatlantic move reveals about Novartis' intention to fundamentally change its approach to drug discovery research and what that transformation may mean for the industry in general.
Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel